Loading...
Loading...
KRYS| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 1.2M |
| Gross Profit | -1.2M |
| Operating Expense | 38.0M |
| Operating I/L | -38.0M |
| Other Income/Expense | 4.8M |
| Interest Income | 4.8M |
| Pretax | -33.2M |
| Income Tax Expense | 1.0M |
| Net Income/Loss | -33.2M |
Krystal Biotech, Inc. is a clinical stage biotechnology company specializing in redosable gene therapy for rare diseases. Its lead product candidate, beremagene geperpavec (B-VEC), is in Phase III clinical study for treating dystrophic epidermolysis bullosa. The company is also developing KB105 for autosomal recessive congenital ichthyosis, KB301 for aged or damaged skin, KB407 for cystic fibrosis, and KB104 for netherton syndrome. Additionally, it has discovery stage product candidates for chronic skin diseases and aesthetic skin conditions. Krystal Biotech, Inc. generates revenue through the development and potential commercialization of these gene therapy treatments.
